To test the ability of the DC subsets in relaying CD4+ T-cell help for CD8+ T-cell priming, we established an in vitro tumor antigen-specific CTL priming platform using the primary DC subsets, CD4+- and CD8+ T-cells purified from human blood (Fig. 2b). The gene discussed is CD8A; the disease is neoplasm.